# OnCo record b7h3 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/b7h3/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "b7h3" ;
  schema:name "B7-H3"@en ;
  schema:description "B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in phase 3 in small-cell lung cancer; whether blocking its immune-dampening role adds anything beyond payload delivery is unresolved."@en ;
  schema:url <https://onco.cc/targets/b7h3/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/CD276>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19137>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103855>, <https://www.uniprot.org/uniprotkb/Q5ZPR3/entry>, <https://www.ncbi.nlm.nih.gov/gene/80381> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5009802> ;
  schema:citation <https://en.wikipedia.org/wiki/CD276> ;
  onco:tag "adc-target" ;
  schema:alternateName "CD276" ;
  onco:targetClass "surface-antigen" ;
  onco:firstDescribed "2001"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/b7-h3-expression/> ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/prostate/> ;
  onco:drugs <https://onco.cc/drugs/yl201/>, <https://onco.cc/drugs/qlc5508/>, <https://onco.cc/drugs/bnt324/>, <https://onco.cc/drugs/bcb-276/> ;
  onco:companies <https://onco.cc/companies/dualitybio/>, <https://onco.cc/companies/myricx-bio/> .